ClinicalTrials.gg
RecruitingNCT04163172Updated Oct 6, 2023

Elbow Hemiarthroplasty Versus ORIF for Distal Humeral Fractures

An interventional study of Surgical treatment of distal humeral fracture with elbow hemiarthroplasty and Surgical treatment of distal humeral fracture with double plating. in Distal Humerus Fracture, Comminuted Fracture and Intra-Articular Fractures, sponsored by Herlev and Gentofte Hospital. Recruiting at 1 site in Denmark. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-10-06.

Sponsored by Herlev and Gentofte Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2020; still recruiting 6 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This is a randomized control trial comparing the outcome of ORIF (open reduction and internal fixation) with EHA (elbow hemiarthroplasty) for distal humeral fractures in patients aged 50 years or above.

Read the detailed description

Intraarticular distal humeral fractures AO/OTA type C2 and C3 pose a surgical challenge despite the evolution of surgical implants and techniques. Open reduction and internal fixation (ORIF) is often preferred as the first choice of treatment, but the results are varying, and sometimes disappointing. Total elbow arthroplasty (TEA) has been widely used for fractures that are not amenable to ORIF in elderly patients, but the mechanical complications remain a challenge, especially in active patients. Elbow hemiarthroplasty (EHA) provides a modern alternative that might avoid the mechanical complications and weight bearing restrictions related to the linked articulation in semiconstrained TEA. There are no studies comparing the results of EHA to that of TEA or ORIF, but case series have reported promising results.

In this study, forty-four patients with AO/OTA type C2 or C3 fractures of distal humerus will be randomized to either ORIF or EHA. The patients will be examined after the operation and at 3 months and 1, 2, 5 and 10 years after the surgery. The main objective of this study is to investigate the best treatment option for distal humeral fractures in patients aged 50 years or above. This can be of value to future patients sustaining these complicated fractures.

02

Conditions studied

  • Distal Humerus Fracture
  • Comminuted Fracture
  • Intra-Articular Fractures
03

In context

Lead sponsor

Herlev and Gentofte Hospital is the lead sponsor of 75 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Distal humeral fracture AO/OTA type C2 or C3 confirmed by plain radiographs with 2 perpendicular views and CT scan.
  2. 1-3 and physically fit for surgery.
  3. Age of 50 years or above.

Exclusion criteria

Exclusion Criteria:

  1. Patients unable to follow the rehabilitation protocol or answer the Danish questionnaires because of physical or cognitive inabilities as evaluated by the recruiting surgeon.
  2. Significant elbow osteoarthritis as evaluated by the recruiting surgeon based on plain radiographs and CT scan.
  3. Fractures that are older than 6 weeks.
  4. Other associated elbow fractures.
  5. Pathological fractures or relevant elbow pathology.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Active comparator
    Elbow hemiarthroplasty

    The Latitude anatomical hemiarthroplasty (WRIGHT -Memphis, Tennessee) for distal humeral fractures.

    Procedure: Surgical treatment of distal humeral fracture with elbow hemiarthroplasty

  • Active comparator
    Open reduction and internal fixation

    Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States) for distal humeral fractures.

    Procedure: Surgical treatment of distal humeral fracture with double plating.

Interventions

  • ProcedureSurgical treatment of distal humeral fracture with elbow hemiarthroplasty

    Latitude anatomical elbow hemiarthroplasty (WRIGHT -Memphis, Tennessee)

  • ProcedureSurgical treatment of distal humeral fracture with double plating.

    Double plating (Synthes - Switzerland and West Chester, Pennsylvania, United States)

06

What researchers measure

Primary outcomes

  1. Oxford Elbow Score (OES)

    The OES is a 12-item patient-administrated questionnaire that measures the quality of life in patients with elbow disorder. There are three unidimensional domains: Elbow function, pain, and social-psychological status. Each question is answered on a 5-point scale with each question contributing equally to the total score.Thus, the total score ranges from 12-60, with 60 being the worst. For ease of presentation the score is converted to a scale from 0-48 with 48 being the best. The outcome can be interpreted based on a 48-point scale: 0 - 19 - poor; 20-29 - fair; 30-39 - good; and 40-48 - excellent. The Danish version which will be used in this study, has been translated and cultural adapted according to the guidelines by Guillemin, Bombardier and Beaton.

    Time frame: 2 years after surgery.

Secondary outcomes

  1. Mayo Elbow Performance Score (MEPS)

    The MEPS is a surgeon-administrated instrument that evaluates the outcome after elbow surgery. There are four domains including: Pain (0-45 points), range of motion (0-20 points), stability (0-10 points) and difficulties in daily activities (0-25 points).The outcome can be interpreted based on a 100 points scale: 0 - 60 - poor; 60-74 - fair; 75-89 - good; and 90-100 - excellent.

    Time frame: 3 months after surgery and 1, 2, 5, and 10 years after surgery.

  2. Pain severity score (VAS)

    Pain is answered on a visual analogue scale (VAS) ranging from 0 to 10, with 10 being the worst and 0 represents a pain free elbow.

    Time frame: 3 months after surgery and 1, 2, 5, and 10 years after surgery.

  3. Range of motion

    Measuring the flexion/extension and supination/pronation arcs in degrees.

    Time frame: 3 months after surgery and 1, 2, 5, and 10 years after surgery.

  4. Patients satisfaction

    Patients satisfaction of the treatment will be recorded using 5-items score with 1 being the worst and 5 represents a very satisfied patient.

    Time frame: 3 months after surgery and 1, 2, 5, and 10 years after surgery.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Al-Hamdani A, Rasmussen JV, Holtz K, Olsen BS. Elbow hemiarthroplasty versus open reduction and internal fixation for AO/OTA type 13 C2 and C3 fractures of distal humerus in patients aged 50 years or above: a randomized controlled trial. Trials. 2020 Jun 8;21(1):497. doi: 10.1186/s13063-020-04418-8. PubMed 32513252 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Dec 2026, 82 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2019
First posted
Nov 14, 2019
StartActual
Feb 1, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2032
Last update
Oct 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04163172
Lead sponsor
Herlev and Gentofte Hospital
Responsible party
Ali Al-Hamdani (Medical doctor, shoulder and elbow surgeon., Herlev and Gentofte Hospital) — Principal investigator
First posted
Nov 14, 2019
Start date
Feb 1, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Oct 6, 2023

Study contacts

Ali Al-Hamdani, MD
Contact
ali.kuthayer.khalil.al-hamdani@regionh.dk
004538673276
Ali Al-Hamdani, MD
principal investigator · Herlev and Gentofte University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion